KAPA
$0.60-0.02 (-2.52%)
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
Recent News
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
The trial consisted of subjects who had not responded to at least one form of hormone therapy previously.
Top Midday Gainers
Longevity Health (XAGE) shares almost doubled amid heavy trading after the company said late Monday
Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Block (XYZ) to Overweight from Equal Weight with a price target of $67, up from $65. The firm sees a “compelling” valuation at current share levels and low expectations for reaccelerated Square Seller growth. Cantor Fitzgerald upgraded Zscaler (ZS) to Overweight from Neutral wit